

**S2 Table: Agreement results between WGS and LPA GenoType MTBDRs/.**

Categorical and statistical agreements between the DST results of the WGS and the LPA GenoType MTBDRs/ were calculated for second-line anti-TB drugs.

<b>Drug</b>	<b>Categorical agreement (%)</b>	<b>Positive agreement</b>	<b>Negative agreement</b>	<b>Kappa value (CI)</b>	<b>SE</b>
MFX/LFX	97.9	0.90	0.98	0.85 (0.67 - 1.00)	0.087
AMI/KAN	100.0	1.00	1.00	1.00 (1.00 - 1.00)	0.000
CAP	95.0	1.00	0.95	0.35 (-0.01 - 0.71)	0.182

**MFX:** Moxifloxacin, **LFX:** Levofloxacin, **AMI:** Amikacin, **KAN:** Kanamycin, **CAP:** Capreomycin, **CI:** 95% Confidence interval, **SE:** Standard error.